These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 19176456)
1. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense. Negri T; Pavan GM; Virdis E; Greco A; Fermeglia M; Sandri M; Pricl S; Pierotti MA; Pilotti S; Tamborini E J Natl Cancer Inst; 2009 Feb; 101(3):194-204. PubMed ID: 19176456 [TBL] [Abstract][Full Text] [Related]
2. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors. Agaram NP; Besmer P; Wong GC; Guo T; Socci ND; Maki RG; DeSantis D; Brennan MF; Singer S; DeMatteo RP; Antonescu CR Clin Cancer Res; 2007 Jan; 13(1):170-81. PubMed ID: 17200352 [TBL] [Abstract][Full Text] [Related]
3. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Chen LL; Trent JC; Wu EF; Fuller GN; Ramdas L; Zhang W; Raymond AK; Prieto VG; Oyedeji CO; Hunt KK; Pollock RE; Feig BW; Hayes KJ; Choi H; Macapinlac HA; Hittelman W; Velasco MA; Patel S; Burgess MA; Benjamin RS; Frazier ML Cancer Res; 2004 Sep; 64(17):5913-9. PubMed ID: 15342366 [TBL] [Abstract][Full Text] [Related]
4. Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Tarn C; Merkel E; Canutescu AA; Shen W; Skorobogatko Y; Heslin MJ; Eisenberg B; Birbe R; Patchefsky A; Dunbrack R; Arnoletti JP; von Mehren M; Godwin AK Clin Cancer Res; 2005 May; 11(10):3668-77. PubMed ID: 15897563 [TBL] [Abstract][Full Text] [Related]
5. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway. Bauer S; Duensing A; Demetri GD; Fletcher JA Oncogene; 2007 Nov; 26(54):7560-8. PubMed ID: 17546049 [TBL] [Abstract][Full Text] [Related]
6. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines. Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968 [TBL] [Abstract][Full Text] [Related]
7. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor. Zheng S; Pan YL; Tao DY; Wang JL; Huang KE Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980 [TBL] [Abstract][Full Text] [Related]
8. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors. Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095 [TBL] [Abstract][Full Text] [Related]
9. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Lasota J; Miettinen M Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355 [TBL] [Abstract][Full Text] [Related]
11. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors]. Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611 [TBL] [Abstract][Full Text] [Related]
12. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient. Tamborini E; Gabanti E; Lagonigro MS; Negri T; Pilotti S; Pierotti MA; Pricl S Cancer Res; 2005 Feb; 65(3):1115; author reply 1115. PubMed ID: 15705916 [No Abstract] [Full Text] [Related]
13. C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines. Santucci MA; Corradi V; Mancini M; Manetti F; Radi M; Schenone S; Botta M ChemMedChem; 2009 Jan; 4(1):118-26. PubMed ID: 19039816 [TBL] [Abstract][Full Text] [Related]
14. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs]. Shiba K; Matsumoto T; Hirota S Gan To Kagaku Ryoho; 2009 Jul; 36(7):1080-5. PubMed ID: 19620796 [TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Bauer S; Yu LK; Demetri GD; Fletcher JA Cancer Res; 2006 Sep; 66(18):9153-61. PubMed ID: 16982758 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic consequences from molecular biology for gastrointestinal stromal tumor patients affected by neurofibromatosis type 1. Mussi C; Schildhaus HU; Gronchi A; Wardelmann E; Hohenberger P Clin Cancer Res; 2008 Jul; 14(14):4550-5. PubMed ID: 18628470 [TBL] [Abstract][Full Text] [Related]
20. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib. Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]